Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Johnson and Johnson
US Army
McKesson
Novartis
Merck
Dow
Boehringer Ingelheim
Deloitte
Colorcon

Generated: February 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021862

« Back to Dashboard

NDA 021862 describes NEVANAC, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug. Additional details are available on the NEVANAC profile page.

The generic ingredient in NEVANAC is nepafenac. There are eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the nepafenac profile page.
Summary for 021862
Tradename:NEVANAC
Applicant:Novartis Pharms Corp
Ingredient:nepafenac
Patents:3
Therapeutic Class:Ophthalmic Agents
Pharmacology for NDA: 021862
Suppliers and Packaging for NDA: 021862
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NEVANAC nepafenac SUSPENSION/DROPS;OPHTHALMIC 021862 NDA Alcon Laboratories, Inc. 0065-0002 N 0065-0002-03
NEVANAC nepafenac SUSPENSION/DROPS;OPHTHALMIC 021862 NDA Physicians Total Care, Inc. 54868-6302 E 54868-6302-0

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION/DROPS;OPHTHALMICStrength0.1%
Approval Date:Aug 19, 2005TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jan 31, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING OCULAR INFLAMMATION
Patent:➤ Try a Free TrialPatent Expiration:Dec 2, 2025Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:Dec 2, 2025Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
UBS
Cerilliant
Colorcon
Teva
Fuji
Federal Trade Commission
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot